

ANTICOAGULATION MAJOR BLEEDING RISK SCORE IN ATRIAL FIBRILLATION

HYPERTENSION Uncontrolled >160 mmHg Systolic	+1
RENAL DISEASE Dialysis / Transplant / Cr > 200µmol/L	+1
LIVER DISEASE Cirrhosis -or- Bilirubin >2x normal with AST/ALP/AP >3x normal	+1
STROKE HISTORY	+1
PRIOR MAJOR BLEEDING OR PREDISPOSITION TO BLEEDING	+1
LABILE INR Unstable / High INR's Time in therapeutic range <60%	+1
MEDICATION PREDISPOSING TO BLEEDING I.E. Aspirin / Clopidogrel / NSAIDSs	+1
AGE > 65	+1
ALCOHOL USE ≥ 8 DRINKS/WEEK	+1

RISK- BENEFIT ANALYSIS

Compare Major Bleeding risk to Stroke risk (CHA₂D-VAS₂) to assist in determining Risk-Benefit of Anticoagulation

MAJOR BLEEDING RISK

SCORE	% RISK - YEAR	PATIENT-YEAR
0	0.9%	1/100
1	3.4%	1/100
2	4.1%	2/100
3	5.8%	3.72/100
4	8.9%	8.7/100
5	9.1%	12.5/100
6	>10%	>12.5/100

RISK- BENEFIT ANALYSIS - QUICK GUIDE

SCORE 0-1 LOW RISK MAJOR BLEEDING	0.9-3.4%	~1/100 Patient-Years
CONSIDER ANTICOAGULATION		
SCORE 2 MODERATE RISK MAJOR BLEEDING	4.1%	~2/100 Patient-Years
CONSIDER ANTICOAGULATION		
SCORE 3+ HIGH RISK MAJOR BLEEDING	5.8-10+%	~4/100 Patient-Years
CONSIDER ALTERNATIVES TO ANTICOAGULATION		